Venture funding for women’s health startups drops sharply after 2024 peak, AI may drive rebound

Venture capital flowing into women’s health companies fell sharply after reaching record levels in 2024. A Silicon Valley Bank report shows total funding dropped from about $3.2 billion in 2024 to roughly $2 billion in 2025, and the share of healthcare deals fell from 7.4% to 5.7%.

Biopharma‑focused startups were hit hardest, with their venture dollars sliding from $1.3 billion to $610 million over the same period. The report suggests the decline reflects a broader shift in the healthcare investment landscape.

Industry observers note that a wider definition of women’s health, encompassing therapeutics, devices and digital health tools, could broaden the addressable market. They also point to growing adoption of artificial intelligence as a catalyst for new business models and product development.

If entrepreneurs can successfully market these expanded opportunities, investors may return with renewed interest, potentially sparking a more sustainable rebound in funding for the sector.